HB1443Introduced in the House
HEALTH CARE AVAILABILITY
Introduced by Nabeela Syed, District 51
What does this bill do?
Plain-English breakdown
Writing a plain-English summary of this bill… this can take a few seconds the first time.
Official description
Reinserts the provisions of the introduced bill with the following changes. Makes changes to defined terms. Replaces references to the Health Care Availability and Access Board, the Health Care Availability and Access Stakeholder Council, and the Health Care Availability and Access Board Fund to the Prescription Drug Affordability Board, the Prescription Drug Affordability Stakeholder Council, and the Prescription Drug Affordability Board Fund. Requires Prescription Drug Affordability Board membership to also include individuals with expertise in the practice of pharmacy. Includes reimbursements from health benefit plans in provisions concerning upper payment limits for payor reimbursements. Requires the Board to maintain financial records and accounts in accordance with generally accepted governmental accounting principles. Provides that the Board shall be deemed a public body for purposes of the Freedom of Information Act and the Open Meetings Act; all records of the Board, including meeting minutes, cost review records, and correspondence, shall be public records subject to disclosure in accordance with the Freedom of Information Act, except as otherwise provided by law; and meetings of the Board shall be open to the public in accordance with the Open Meetings Act. Requires the Board to establish an operational plan for distribution and access to a drug with an upper payment limit before the Board reviews specific drugs for affordability and establishes any upper payment limits. Provides that the Board shall prioritize establishing and implementing upper payment limits for the 10 prescription drug products with a Medicare Maximum Fair Price that went into effect in 2026 before proceeding with upper payment limits on other prescription drug products with a Medicare Maximum Fair Price or affordability reviews for any other prescription drug products. Adds more items to the list of information that may be included to conduct an affordability review. Provides that the Board may suspend an upper payment limit if it determines that there is a shortage of the drug in the State unless the Board determines that the shortage was caused by a manufacturer or its agent. Changes expertise requirements for membership of the Prescription Drug Affordability Stakeholder Council. Establishes specified exemptions for the Department of Healthcare and Family Services and other State departments in provisions concerning protections and other Board considerations. Provides that any upper payment limit established by the Board shall not apply to prescription drug products purchased by the Department of Healthcare and Family Services for the medical assistance program under Article V of the Illinois Public Aid Code or to a health care plan serving Medicaid populations that provides, arranges for, pays for, or reimburses the cost of any health care service for persons who are enrolled under the medical assistance program under Article V of the Illinois Public Aid Code unless, after consultation with and approval of the Director of Healthcare and Family Services, it is determined that the upper payment limit would reduce costs to the State. Provides that, if a prescription drug product subject to an upper payment limit established under the Act is intended to be made available for purchase by pharmacies, distributors, or wholesalers licensed in the State, it shall be available at a price that does not exceed the upper payment limit (rather than a wholesaler or distributor shall make any prescription drug product that is subject to an upper payment limit established under the Act available for purchase by pharmacies licensed in this State at a price that does not exceed the established upper payment limit), and, if a wholesaler or distributor acquires a prescription drug product subject to an upper payment limit at a price that exceeds the upper payment limit, the wholesaler or distributor is entitled to a chargeback or rebate equal to the difference between the price and the upper payment limit from the entity that sold the product to the wholesaler or distributor. Changes the required reporting date for the Board concerning the operation of the generic drug market in the United States to June 1, 2027 (rather than June 1, 2025). Requires the Board to notify the General Assembly if 5 years have passed without any litigation hindering Board operations. Provides that the Act is repealed 5 years after the effective date of the Act. Makes other changes. Effective 180 days after becoming law.
Where it stands
House Floor Amendment No. 3 Rule 19(c) / Re-referred to Rules Committee
April 17, 2026
How did lawmakers vote?
HouseStage: House Health Care Availability & Access Committee · April 16, 2026
9
Yes
5
No
0
Absent or Not Voting
14 representatives recorded in this House vote. Colors show vote categories only, not whether a vote was good or bad.
See how each representative voted
| Representative | District | Vote |
|---|---|---|
| Yolanda Morris | 9 | Yes |
| Kelly Cassidy | 14 | Yes |
| Theresa Mah | 24 | Yes |
| Michael Crawford | 31 | Yes |
| Jennifer Sanalitro | 48 | No |
| Nabeela Syed | 51 | Yes |
| Nicolle Grasse | 53 | Yes |
| Bradley Fritts | 74 | No |
| Camille Lilly | 78 | Yes |
| Jackie Haas | 79 | No |
Bill history
Filed with the Clerk by Rep. Nabeela Syed
First Reading
Referred to Rules Committee
Added Co-Sponsor Rep. Katie Stuart
Added Co-Sponsor Rep. Diane Blair-Sherlock
Added Co-Sponsor Rep. Janet Yang Rohr
Added Co-Sponsor Rep. Theresa Mah
Added Co-Sponsor Rep. Abdelnasser Rashid
Added Co-Sponsor Rep. Mary Beth Canty
Added Co-Sponsor Rep. Kelly M. Cassidy
Assigned to Health Care Availability & Accessibility Committee
Added Co-Sponsor Rep. Will Guzzardi
Added Co-Sponsor Rep. Michelle Mussman
Added Co-Sponsor Rep. Nicolle Grasse
Added Co-Sponsor Rep. Norma Hernandez
Added Co-Sponsor Rep. Kevin John Olickal
Added Co-Sponsor Rep. Gregg Johnson
To Prescription Drug Affordability Board
Added Co-Sponsor Rep. Camille Y. Lilly
Added Co-Sponsor Rep. Suzanne M. Ness
Added Co-Sponsor Rep. Debbie Meyers-Martin
Added Co-Sponsor Rep. Anne Stava
Added Co-Sponsor Rep. Anna Moeller
Added Co-Sponsor Rep. Maura Hirschauer
Added Co-Sponsor Rep. Dagmara Avelar
Rule 19(a) / Re-referred to Rules Committee
Added Co-Sponsor Rep. La Shawn K. Ford
Added Co-Sponsor Rep. Joyce Mason
Added Co-Sponsor Rep. Kimberly Du Buclet
Added Co-Sponsor Rep. Michael Crawford
Added Co-Sponsor Rep. Lisa Davis
Added Co-Sponsor Rep. Rita Mayfield
Assigned to Health Care Availability & Accessibility Committee
Do Pass / Short Debate Health Care Availability & Accessibility Committee; 008-004-000
Placed on Calendar 2nd Reading - Short Debate
Added Co-Sponsor Rep. Laura Faver Dias
Added Co-Sponsor Rep. Emanuel "Chris" Welch
Balanced Budget Note Requested by Rep. Nabeela Syed
Correctional Note Requested by Rep. Nabeela Syed
Fiscal Note Requested by Rep. Nabeela Syed
Home Rule Note Requested by Rep. Nabeela Syed
Housing Affordability Impact Note Requested by Rep. Nabeela Syed
Judicial Note Requested by Rep. Nabeela Syed
Land Conveyance Appraisal Note Requested by Rep. Nabeela Syed
Pension Note Requested by Rep. Nabeela Syed
Racial Impact Note Requested by Rep. Nabeela Syed
State Debt Impact Note Requested by Rep. Nabeela Syed
State Mandates Fiscal Note Requested by Rep. Nabeela Syed
House Floor Amendment No. 1 Filed with Clerk by Rep. Nabeela Syed
House Floor Amendment No. 1 Referred to Rules Committee
House Floor Amendment No. 1 Rules Refers to Health Care Availability & Accessibility Committee
Second Reading - Short Debate
Held on Calendar Order of Second Reading - Short Debate
Fiscal Note Filed
House Floor Amendment No. 2 Filed with Clerk by Rep. Nabeela Syed
House Floor Amendment No. 2 Referred to Rules Committee
House Floor Amendment No. 2 Rules Refers to Health Care Availability & Accessibility Committee
House Floor Amendment No. 3 Filed with Clerk by Rep. Nabeela Syed
House Floor Amendment No. 3 Referred to Rules Committee
House Floor Amendment No. 3 Rules Refers to Health Care Availability & Accessibility Committee
House Floor Amendment No. 4 Filed with Clerk by Rep. Nabeela Syed
House Floor Amendment No. 4 Referred to Rules Committee
House Floor Amendment No. 4 Rules Refers to Health Care Availability & Accessibility Committee
House Floor Amendment No. 4 Recommends Be Adopted Health Care Availability & Accessibility Committee; 009-005-000
Balanced Budget Note Requested - Withdrawn by Rep. Nabeela Syed
Correctional Note Requested - Withdrawn by Rep. Nabeela Syed
Fiscal Note Requested - Withdrawn by Rep. Nabeela Syed
Home Rule Note Requested - Withdrawn by Rep. Nabeela Syed
Housing Affordability Impact Note Requested - Withdrawn by Rep. Nabeela Syed
Judicial Note Requested - Withdrawn by Rep. Nabeela Syed
Land Conveyance Appraisal Note Requested - Withdrawn by Rep. Nabeela Syed
Pension Note Requested - Withdrawn by Rep. Nabeela Syed
State Mandates Fiscal Note Requested - Withdrawn by Rep. Nabeela Syed
Racial Impact Note Requested - Withdrawn by Rep. Nabeela Syed
State Debt Impact Note Requested - Withdrawn by Rep. Nabeela Syed
House Floor Amendment No. 4 Adopted
Added Co-Sponsor Rep. Yolonda Morris
Added Chief Co-Sponsor Rep. Will Guzzardi
Removed Co-Sponsor Rep. Will Guzzardi
Placed on Calendar Order of 3rd Reading - Short Debate
Chair Rules Standard Debate
Placed on Calendar Order of 3rd Reading - Standard Debate
Rule 19(a) / Re-referred to Rules Committee
House Floor Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee
House Floor Amendment No. 2 Rule 19(c) / Re-referred to Rules Committee
House Floor Amendment No. 3 Rule 19(c) / Re-referred to Rules Committee
Verify the information
Our commitment to neutrality
We provide factual information only. We never tell you which politicians or bills to support, and we do not rank, score, or endorse anyone.